SYMBION HEALTH LIMITED (ASX.SYB)

former shareholders in this company may have unclaimed money arising from the compulsory acquisition of their shares - deListed provides a tracing service for a small administration fee that identifies where people can find unclaimed monies arising from compulsory acquisitions and also from dividend distributions, super contributions, inoperative bank, building society or credit union accounts, bequests and other sources - please click here for access to our Lost shares, Lost money?? service

delisted following the receipt of the compulsory acquisition notice from Primary Health Care Limited

we understand Primary Health Care was successful with an offer of $4.05 cash per share (the offer was reduced by 5 cents to $4.05 being a fully franked interim dividend declared by Symbion record date 7 March 2008)

the Company will be removed from the official list of ASX Limited at the close of trading on Friday, 9 May 2008 in accordance with listing rule 17.14

Primary Health Care Limited yesterday completed the compulsory acquisition of the Symbion Health Limited shares held by Symbion shareholders

Metcash and Sigma are investigating the possibility of jointly bidding for Symbion's consumer brands and pharmaceutical wholesaling assets - they are in the early stages of the process and shareholders and investors are advised to exercise caution

securities suspended from quotation at the close of trading on Thursday 20 March 2008, following receipt of the compulsory acquisition notice from Primary Health Care Limited, in accordance with listing rule 17.4

we understand that on or about this date the company undertook, proposed to undertake or was the subject of the following corporate action: - Healthscope to acquire SYB shares - this corporate event may appear elsewhere in this company record

Mayne Group Limited (Mayne) undertook a number of transactions to separate the ownership of the international pharmaceutical business (to Mayne Pharma and its subsidiaries) - Mayne (now Symbion Health Limited) retained the domestic healthcare businesses - as a result of the demerger, Mayne shareholders held shares in both Symbion Health and Mayne Pharma - the demerger was undertaken via a Scheme of Arrangement whereby Mayne undertook a capital reduction under which a total of approximately $1.56 billion of contributed capital was returned to Mayne shareholders (capital reduction amount) - this amounted to approximately $2.45 per ordinary issued Mayne share - the capital reduction amount was applied on behalf of Mayne shareholders for the subscription of approximately 636 million new shares in Mayne Pharma - Mayne shareholders subscribed for one new Mayne Pharma share for every one Mayne share they held before the demerger and Mayne Pharma used the funds received on the issue of the new shares to repay outstanding loans to Mayne

name changed from Mayne Group Limited